Stock Analysis·← Pickers

SCPH

scPharmaceuticals Inc.

scPharmaceuticals Inc. (SCPH) is currently in an uptrend, trading above both the 50-day and 200-day moving averages. RSI is at 64.4, with 3/3 trend checks passing.

Price
$5.67
2026-07-16
Trend score
3/3
Uptrend
RSI (14)
64.4
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

SCPH with MA50 and MA200

5.844.883.932.982.0210/2301/2204/1707/1510/08
SCPH2024-10-232025-10-08
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$5.35+5.91% vs price
MA200
$3.89+45.94% vs price
RSI (14)
64.4Neutral zone
MACD Signal
MixedMACD near signal line
Macro Support
$3.71–$3.8132.8% below price · 2 touches
Support Quality
2 touches0.6× zone volume
Chart Summary
Trend summary for SCPH

scPharmaceuticals Inc. (SCPH) is still trading in a constructive trend overall. The latest available price is $5.67, and 3 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 5.9% and above the 200-day moving average by 45.9%.

Momentum and stretch context

SCPH currently has an RSI reading of 64.4, which leans mildly positive without looking too stretched. In other words, momentum is supportive, but not yet extreme enough to dominate the entire chart read.

What traders may watch next

For traders reviewing SCPH next, the key question is whether the trend still looks healthy or whether price has started to outrun itself. A strong uptrend can stay strong, but entries often become more difficult when price is already extended, so many traders will watch for pullbacks, support reactions, or fresh bases rather than chasing strength blindly.

Company profile

About scPharmaceuticals Inc.

scPharmaceuticals Inc. is a pharmaceutical firm dedicated to developing and commercializing a variety of medicinal products. Its primary investigational therapy, FUROSCIX, is a specialized formulation of furosemide delivered through an on-body infusor, intended for managing congestion in heart failure patients. The company's pipeline also encompasses scCeftriaxone, an antibiotic aimed at treating infections caused by both gram-positive and gram-negative bacteria, as well as the scCarbapenem program, another antibiotic designed for gram-negative bacterial infections. Additionally, scPharmaceuticals has entered into a collaboration agreement with West Pharmaceutical Services, Inc. for the advancement of a single-use SmartDose device. Founded in 2013, the company's main operations are based in Burlington, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
John H. Tucker
Employees
162
Market cap
$302.2M
Beta
0.30
52-week range
$1.94 – $6.28
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
17 Nov 2017
ISIN
US8106481059
CUSIP
810648105
Company profile data from Financial Modeling Prep. SCPH listed on NASDAQ.
Share dilution

SCPH shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Sept 2018Jun 2025
Shares outstanding (latest)
53.7M
Since Sept 2018
+189.3%
Trend
More shares outstanding
Historical shares-outstanding data from Financial Modeling Prep. SCPH28 data points from Sept 2018 to Jun 2025.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about SCPH

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.